To visit the old Ventura website, click here.
Ventura Wealth Clients Login here
Refer and earnSupport
logosearch
Create Account
hamburger
home
breadcrumbStocks
breadcrumbMankind Pharma Limited Share Price
breadcrumbResults

Quarterly results

rupeeShow figures in :
rupeeShow figures in :

Quarterly results

Quarter ended on March 31, 2025Data in Crores of INR
Revenue
₹ 3.08K+26.15% from last year
Operating profits
₹ 934.52+36.78% from last year
Net income
₹ 422.33-10.93% from last year

Financial reports

Data is unavailable

INCOME STATEMENTinfo2
Data in Crores of INR

Data is unavailable

BALANCE SHEETinfo2
Data in Crores of INR
FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016FY 2015
Net worth14332.399363.097435.226155.234722.003485.312823.052880.912927.142256.962054.78
Fixed assets19004.484539.954245.283582.771658.941594.041399.461013.77793.31446.98276.66
Debt8300.47196.04162.64868.03234.53128.05270.16407.1912.622.420.02
docView detailed balance sheet
arrow
CASH FLOWinfo2
Data in Crores of INR
FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016FY2015
Operating2413.382152.441813.30919.781137.241072.20600.37639.22627.68537.11279.67
Investing -12682.95-2081.69-1054.13-1369.14-1222.21-439.15-444.34-504.90-624.96-151.65-347.90
Financing 10232.565.27-739.73604.62-7.81-526.97-175.15-88.812.32-360.869.34

Financial ratios

Profitability ratiosinfo2
ROA10.15%
ROE16.98%
ROCE18.32%
EPS48.25%
Net profit margin16.44%
Operating profit margin28.06%
Dividend per share
Operational ratiosinfo2
Quick ratio0.86%
Current ratio1.23%
Interest coverage6.83%
Assets turnover0.64%
Debt to equity0.58%
Valuation ratiosinfo2
P/E ratio53.65%
P/B ratio7.47%
Dividend yield
EV/EBITDA
Mankind Pharma Limited is engaged in developing, manufacturing and marketing a diverse range of pharmaceutical formulations across various acute and chronic therapeutic areas, as well as several consumer healthcare products. The company is engaged in developing, manufacturing and marketing a diverse range of pharmaceutical formulations across various acute and chronic therapeutic areas, as well as several consumer healthcare products. It operates at the intersection of the Indian pharmaceutical formulations and consumer healthcare sectors with the aim of providing quality products at affordable prices, and has an established track record of building and scaling brands in-house. It has created many brands in its pharmaceutical business.
personal

Grow your wealth with more research recommendations

+91